Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils

Wan Chun Sun, James N. Moore, David J. Hurley, Michel L. Vandenplas, Joel M. Linden, Thomas F. Murray

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective - To evaluate anti-inflammatory effects of several novel adenosine receptor agonists and to determine their specificity for various adenosine receptor subtypes on neutrophils, cells heterologously expressing equine adenosine receptors, or equine brain membranes. Sample Population - Neutrophils isolated from 8 healthy horses. Procedures - Radioligand binding experiments were performed to compare binding affinities of adenosine receptor agonists to equine adenosine A1, A2A, and A3 receptor subtypes. Effects of these agonists on endotoxin-induced production of reactive oxygen species (ROS) by equine neutrophils and roles of specific adenosine receptor subtypes and cAMP production in mediating these effects were determined. Results - Radioligand binding experiments yielded a ranked order of affinity for the brain equine A2A receptor on the basis of 50% inhibitory concentrations (IC50) of the agonists as follows: ATL307 (IC50 = 1.9nM) and ATL313 > ATL309 and ATL310 > ATL202 > 2-([p-2-carboxyethyl] phenylethylamino)- 5′-N-ethylcarboxyamidoadenosine > 5′- N-ethylcarboxamidoadenosine. Furthermore, ATL313 had approximately 100-fold greater selectivity for A2A over A1 and A3 receptors. In functional assays with equine neutrophils, the compounds inhibited endotoxin-induced ROS production and stimulated production of cAMP with the same ranked order of potency. Results of experiments performed with selective adenosine receptor antagonists indicated that functional effects of ATL313 were via stimulation of A2A receptors. Conclusions and Clinical Relevance - Results indicated that activation of A2A receptors exerted anti-inflammatory effects on equine neutrophils and that stable, highly selective adenosine A2A receptor agonists may be developed for use in management of horses and other domestic animals with septic and nonseptic inflammatory diseases.

Original languageEnglish
Pages (from-to)981-987
Number of pages7
JournalAmerican Journal of Veterinary Research
Volume68
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Adenosine A2 Receptor Agonists
adenosine
agonists
Horses
neutrophils
Neutrophils
horses
receptors
Purinergic P1 Receptors
Purinergic P1 Receptor Agonists
Inhibitory Concentration 50
inhibitory concentration 50
Endotoxins
Reactive Oxygen Species
Anti-Inflammatory Agents
endotoxins
Adenosine A3 Receptors
anti-inflammatory activity
Adenosine-5'-(N-ethylcarboxamide)
Adenosine A2A Receptors

All Science Journal Classification (ASJC) codes

  • veterinary(all)

Cite this

Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils. / Sun, Wan Chun; Moore, James N.; Hurley, David J.; Vandenplas, Michel L.; Linden, Joel M.; Murray, Thomas F.

In: American Journal of Veterinary Research, Vol. 68, No. 9, 09.2007, p. 981-987.

Research output: Contribution to journalArticle

Sun, Wan Chun ; Moore, James N. ; Hurley, David J. ; Vandenplas, Michel L. ; Linden, Joel M. ; Murray, Thomas F. / Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils. In: American Journal of Veterinary Research. 2007 ; Vol. 68, No. 9. pp. 981-987.
@article{c62fd0e39bcf403b9028643435cf03dd,
title = "Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils",
abstract = "Objective - To evaluate anti-inflammatory effects of several novel adenosine receptor agonists and to determine their specificity for various adenosine receptor subtypes on neutrophils, cells heterologously expressing equine adenosine receptors, or equine brain membranes. Sample Population - Neutrophils isolated from 8 healthy horses. Procedures - Radioligand binding experiments were performed to compare binding affinities of adenosine receptor agonists to equine adenosine A1, A2A, and A3 receptor subtypes. Effects of these agonists on endotoxin-induced production of reactive oxygen species (ROS) by equine neutrophils and roles of specific adenosine receptor subtypes and cAMP production in mediating these effects were determined. Results - Radioligand binding experiments yielded a ranked order of affinity for the brain equine A2A receptor on the basis of 50{\%} inhibitory concentrations (IC50) of the agonists as follows: ATL307 (IC50 = 1.9nM) and ATL313 > ATL309 and ATL310 > ATL202 > 2-([p-2-carboxyethyl] phenylethylamino)- 5′-N-ethylcarboxyamidoadenosine > 5′- N-ethylcarboxamidoadenosine. Furthermore, ATL313 had approximately 100-fold greater selectivity for A2A over A1 and A3 receptors. In functional assays with equine neutrophils, the compounds inhibited endotoxin-induced ROS production and stimulated production of cAMP with the same ranked order of potency. Results of experiments performed with selective adenosine receptor antagonists indicated that functional effects of ATL313 were via stimulation of A2A receptors. Conclusions and Clinical Relevance - Results indicated that activation of A2A receptors exerted anti-inflammatory effects on equine neutrophils and that stable, highly selective adenosine A2A receptor agonists may be developed for use in management of horses and other domestic animals with septic and nonseptic inflammatory diseases.",
author = "Sun, {Wan Chun} and Moore, {James N.} and Hurley, {David J.} and Vandenplas, {Michel L.} and Linden, {Joel M.} and Murray, {Thomas F.}",
year = "2007",
month = "9",
doi = "10.2460/ajvr.68.9.981",
language = "English",
volume = "68",
pages = "981--987",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "9",

}

TY - JOUR

T1 - Pharmacologic characterization of novel adenosine A2A receptor agonists in equine neutrophils

AU - Sun, Wan Chun

AU - Moore, James N.

AU - Hurley, David J.

AU - Vandenplas, Michel L.

AU - Linden, Joel M.

AU - Murray, Thomas F.

PY - 2007/9

Y1 - 2007/9

N2 - Objective - To evaluate anti-inflammatory effects of several novel adenosine receptor agonists and to determine their specificity for various adenosine receptor subtypes on neutrophils, cells heterologously expressing equine adenosine receptors, or equine brain membranes. Sample Population - Neutrophils isolated from 8 healthy horses. Procedures - Radioligand binding experiments were performed to compare binding affinities of adenosine receptor agonists to equine adenosine A1, A2A, and A3 receptor subtypes. Effects of these agonists on endotoxin-induced production of reactive oxygen species (ROS) by equine neutrophils and roles of specific adenosine receptor subtypes and cAMP production in mediating these effects were determined. Results - Radioligand binding experiments yielded a ranked order of affinity for the brain equine A2A receptor on the basis of 50% inhibitory concentrations (IC50) of the agonists as follows: ATL307 (IC50 = 1.9nM) and ATL313 > ATL309 and ATL310 > ATL202 > 2-([p-2-carboxyethyl] phenylethylamino)- 5′-N-ethylcarboxyamidoadenosine > 5′- N-ethylcarboxamidoadenosine. Furthermore, ATL313 had approximately 100-fold greater selectivity for A2A over A1 and A3 receptors. In functional assays with equine neutrophils, the compounds inhibited endotoxin-induced ROS production and stimulated production of cAMP with the same ranked order of potency. Results of experiments performed with selective adenosine receptor antagonists indicated that functional effects of ATL313 were via stimulation of A2A receptors. Conclusions and Clinical Relevance - Results indicated that activation of A2A receptors exerted anti-inflammatory effects on equine neutrophils and that stable, highly selective adenosine A2A receptor agonists may be developed for use in management of horses and other domestic animals with septic and nonseptic inflammatory diseases.

AB - Objective - To evaluate anti-inflammatory effects of several novel adenosine receptor agonists and to determine their specificity for various adenosine receptor subtypes on neutrophils, cells heterologously expressing equine adenosine receptors, or equine brain membranes. Sample Population - Neutrophils isolated from 8 healthy horses. Procedures - Radioligand binding experiments were performed to compare binding affinities of adenosine receptor agonists to equine adenosine A1, A2A, and A3 receptor subtypes. Effects of these agonists on endotoxin-induced production of reactive oxygen species (ROS) by equine neutrophils and roles of specific adenosine receptor subtypes and cAMP production in mediating these effects were determined. Results - Radioligand binding experiments yielded a ranked order of affinity for the brain equine A2A receptor on the basis of 50% inhibitory concentrations (IC50) of the agonists as follows: ATL307 (IC50 = 1.9nM) and ATL313 > ATL309 and ATL310 > ATL202 > 2-([p-2-carboxyethyl] phenylethylamino)- 5′-N-ethylcarboxyamidoadenosine > 5′- N-ethylcarboxamidoadenosine. Furthermore, ATL313 had approximately 100-fold greater selectivity for A2A over A1 and A3 receptors. In functional assays with equine neutrophils, the compounds inhibited endotoxin-induced ROS production and stimulated production of cAMP with the same ranked order of potency. Results of experiments performed with selective adenosine receptor antagonists indicated that functional effects of ATL313 were via stimulation of A2A receptors. Conclusions and Clinical Relevance - Results indicated that activation of A2A receptors exerted anti-inflammatory effects on equine neutrophils and that stable, highly selective adenosine A2A receptor agonists may be developed for use in management of horses and other domestic animals with septic and nonseptic inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=34548617789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548617789&partnerID=8YFLogxK

U2 - 10.2460/ajvr.68.9.981

DO - 10.2460/ajvr.68.9.981

M3 - Article

VL - 68

SP - 981

EP - 987

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 9

ER -